Journal List > Korean J Schizophr Res > v.15(2) > 1057772

Jang, Kim, Lee, Kim, Bae, Kim, Shin, and Yoon: Attitude Toward Antipsychotic Treatment According to Patients' Awareness of the Name of Their Illness in Patients with Schizophrenia

Abstract

Objectives

This study compared attitudes toward antipsychotic treatment according to awareness of the name of their illness in patients with schizophrenia.

Methods

Information on sociodemographic and clinical characteristics, including awareness of the importance of antipsychotic treatment, was obtained through a self-report questionnaire. The Drug Attitude Inventory (DAI) was administered. The data were compared according to awareness of the name of their illness.

Results

The study analyzed data for 199 patients with schizophrenia. Of these, 115 patients (57.8%) were aware that their illness was called schizophrenia, while 84 patients (42.2%) knew it by their psychotic symptoms or as another mental illness, such as depression. The patients aware of the name of their illness had significantly longer durations of illness and higher scores on the DAI. They were significantly more likely to have stopped taking medication on their own accord and to agree with the importance of antipsychotic treatment. Statistical significance was sustained in a logistic regression analysis after adjusting for the duration of illness and study site, except for the DAI score, which had borderline significance (p=0.055). In subjects with duration of illness ≥5 years, patients aware of the name of their illness had significantly higher scores on the DAI.

Conclusion

Awareness of the name of their illness was associated with awareness of the importance of, and a positive attitude toward, antipsychotic treatments in patients. Psycho-education, including telling the patient the correct name of his or her illness, might be needed for maintaining antipsychotic treatment in patients with chronic schizophrenia.

Figures and Tables

Fig. 1
Scores on Drug Attitude Inventory according to the awareness of illness name in participants with duration of illness (DOI)<5 year or ≥5 year. Bar represents median and interquartile range. (A) p-value=0.401 and (B) p-value=0.033 by Mann-Whitney U test.
kjsr-15-106-g001
Table 1
Socio-demographic characteristics according to the awareness of illness name
kjsr-15-106-i001

N : number, IQR : interquartile range, OPD : Outpatient department

Table 2
Clinical characteristics according to the awareness of illness name
kjsr-15-106-i002

*: Available only in patients taking oral antipsychotic drugs, : Adjusted for duration of illness and type of hospital. N : number, IQR : interquartile range, Hx : history

References

1. Kane JM. Schizophrenia. N Engl J Med. 1996. 334:34–41.
crossref
2. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry. 1975. 132:1237–1245.
crossref
3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005. 353:1209–1223.
crossref
4. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl. 1994. 382:16–24.
crossref
5. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002. 106:286–290.
crossref
6. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002. 63:892–909.
crossref
7. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006. 67:1542–1550.
crossref
8. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002. 159:1653–1664.
crossref
9. You JH, Woo YS, Hahn C, Choi JW, Ko HJ. Predicting Factors Associated with Drug Compliance in Psychiatric Outpatients of a University Hospital. Korean J Psychopharmacol. 2010. 21:29–34.
10. Kwon JS, Shin SW, Cheong YM, Park KH. Medication Compliance in Psychiatric Outpatients of a University Hospital. J Korean Neuropsychiatr Assoc. 1997. 36:523–529.
11. Kim SW, Yoon JS, Choi SK. Survey of medication adherence in patients with schizophrenia-Korean ADHES data. Hum Psychopharmacol. 2006. 21:533–537.
crossref
12. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006. 67:453–460.
crossref
13. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010. 176:109–113.
crossref
14. Dutta R, Murray RM, Allardyce J, Jones PB, Boydell J. Early risk factors for suicide in an epidemiological first episode psychosis cohort. Schizophr Res. 2011. 126:11–19.
crossref
15. Linden M, Godemann F. The differentiation between 'lack of insight' and 'dysfunctional health beliefs' in schizophrenia. Psychopathology. 2007. 40:236–241.
crossref
16. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993. 150:873–879.
crossref
17. Kampman O, Laippala P, Väänänen J, Koivisto E, Kiviniemi P, Kilkku N, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002. 110:39–48.
crossref
18. David AS. Insight and psychosis. Br J Psychiatry. 1990. 156:798–808.
crossref
19. Yen CF, Chen CS, Ko CH, Yeh ML, Yang SJ, Yen JY, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci. 2005. 59:403–409.
crossref
20. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005. 62:717–724.
21. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Association between attitude toward medication and neurocognitive function in schizophrenia. Clin Neuropharmacol. 2006. 29:197–205.
crossref
22. Kim SW, Yoon JS, Lee MS, Lee HY. The analysis of newspaper-articles on psychosis. J Korean Neuropsychiatr Assoc. 2000. 39:838–848.
23. Kim SW, Kim SY, Yoo JA, Bae KY, Kim JM, Shin IS, et al. The stigmatization of psychosis in Korean Newspaper articles. Korean J Schizophr Res. 2011. 14:42–49.
24. Ono Y, Satsumi Y, Kim Y, Iwadate T, Moriyama K, Nakane Y, et al. Schizophrenia: is it time to replace the term? Psychiatry Clin Neurosci. 1999. 53:335–341.
crossref
25. Chung KF, Chan JH. Can a less pejorative Chinese translation for schizophrenia reduce stigma? A study of adolescents' attitudes toward people with schizophrenia. Psychiatry Clin Neurosci. 2004. 58:507–515.
crossref
26. Kim SW, Jang JE, Kim JM, Shin IS, Ban DH, Choi B, et al. Comparison of Stigma according to the Term Used for Schizophrenia: Split-Mind Disorder vs. Attunement Disorder. J Korean Neuropsychiatr Assoc. 2012. 51:210–217.
crossref
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1994. 4th ed. Washington DC: American Psychiatric Press Inc.
28. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983. 13:177–183.
crossref
29. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of Korean version of Drug Attitude Inventory (KDAI-10). Korean J Psychopharmacol. 2005. 16:480–487.
30. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994. 51:826–836.
crossref
31. Thompson KN, McGorry PD, Harrigan SM. Reduced awareness of illness in first-episode psychosis. Compr Psychiatry. 2001. 42:498–503.
crossref
32. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010. 20:310–316.
crossref
33. Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006. 21:29–33.
crossref
34. Wong MM, Chen EY, Lui SS, Tso S. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses. 2011. 5:135–141.
crossref
35. Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry. 2006. 189:204–212.
36. Amador XF, Gorman JM. Psychopathologic domains and insight in schizophrenia. Psychiatr Clin North Am. 1998. 21:27–42.
crossref
37. Marková IS, Berrios GE. The meaning of insight in clinical psychiatry. Br J Psychiatry. 1992. 160:850–860.
crossref
38. Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis. 1996. 184:653–659.
crossref
39. Donohoe G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry. 2001. 16:293–298.
crossref
40. Kozuki Y, Froelicher ES. Lack of awareness and nonadherence in schizophrenia. West J Nurs Res. 2003. 25:57–74.
crossref
41. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003. 108:439–446.
crossref
42. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM, et al. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999. 187:102–108.
crossref
43. Watson PW, Garety PA, Weinman J, Dunn G, Bebbington PE, Fowler D, et al. Emotional dysfunction in schizophrenia spectrum psychosis: the role of illness perceptions. Psychol Med. 2006. 36:761–770.
crossref
44. Tait L, Birchwood M, Trower P. Predicting engagement with services for psychosis: insight, symptoms and recovery style. Br J Psychiatry. 2003. 182:123–128.
crossref
45. Lincoln TM, Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. Schizophr Bull. 2007. 33:1324–1342.
crossref
46. Park JI, Chung YC. Renaming the term 'schizophrenia' in Korea. Korean J Schizophr Res. 2008. 11:107–117.
47. Green RS, Ganter AB. Telling patients and families the psychiatric diagnosis: a survey of psychiatrists. Hosp Community Psychiatry. 1987. 38:666–668.
crossref
48. Mitchell AJ. Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists. Support Care Cancer. 2007. 15:819–828.
crossref
49. Clafferty RA, McCabe E, Brown KW. Conspiracy of silence? Telling patients with schizophrenia their diagnosis. Psychiatr Bull R Coll Psychiatr. 2001. 25:339.
crossref
50. Clafferty RA, McCabe E, Brown KW. Telling patients with schizophrenia their diagnosis. Patients should be informed about their illness. BMJ. 2000. 321:384–385.
51. Atkinson JM. To tell or not to tell the diagnosis of schizophrenia. J Med Ethics. 1989. 15:21–24.
crossref
52. Nishimura Y, Ono H. Ono Y, editor. A study on renaming schizophrenia and informing diagnosis. Studies on the effects of renaming psychiatric disorders. 2005. Tokyo: Ministry of Health, Labor and Welfare;6–13. (in Japanese).
53. Sato M, Koiwa M. Ono Y, editor. Prevalence of "Togo Shitcho Sho" (schizophrenia) and the ripple effect. Studies on the effects of renaming psychiatric disorders. 2005. Tokyo: Ministry of Health, Labor and Welfare;14–18. (in Japanese).
54. Mitsumoto Sato. Integration disorder: the process and effects of renaming schizophrenia in Japan. Korean J Schizophr Res. 2008. 11:65–65.
55. Staring AB, Van der Gaag M, Van den Berge M, Duivenvoorden HJ, Mulder CL. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res. 2009. 115:363–369.
crossref
56. Cooke M, Peters E, Fannon D, Anilkumar AP, Aasen I, Kuipers E, et al. Insight, distress and coping styles in schizophrenia. Schizophr Res. 2007. 94:12–22.
crossref
57. Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007. 33:192–199.
crossref
58. Schwartz RC, Smith SD. Suicidality and psychosis: the predictive potential of symptomatology and insight into illness. J Psychiatr Res. 2004. 38:185–191.
crossref
59. Amador XF, Friedman JH, Kasapis C, Yale SA, Flaum M, Gorman JM. Suicidal behaviour in schizophrenia and its relationship to awareness of illness. Am J Psychiatry. 1996. 153:1185–1188.
60. Schwartz RC, Petersen S. The relationship between insight and suicidality among patients with schizophrenia. J Nerv Ment Dis. 1999. 187:376–378.
crossref
61. Schwartz RC. Insight and suicidality in schizophrenia: a replication study. J Nerv Ment Dis. 2000. 188:235–237.
crossref
62. Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res. 2003. 60:71–80.
crossref
63. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011. 132:42–49.
crossref
TOOLS
Similar articles